Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Mitral Regurgitation Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Mitral Regurgitation. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Mitral Regurgitation clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 4 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Mitrassist Lifesciences Limited Co., Ltd. (1), Chinese Academy of Medical Sciences, Fuwai Hospital (1), Medical University of Vienna (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Polymer Prosthetic Heart Valve (device, 1 trial), followed by Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Mitral Regurgitation trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07097740

Early Feasibility Study of Surgical Implantation of a Polymer Prosthetic Mitral and Aortic Valve

The goal of this clinical trial is to explore the early feasibility, initial safety, and efficacy of surgical implantation of a polymer prosthetic heart valve in patients...

Sponsor: Mitrassist Lifesciences Limited Co., Ltd.Enrolling: 101 location
RECRUITINGPhase 4NCT07007143

STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication...

Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups)....

Sponsor: Chinese Academy of Medical Sciences, Fuwai HospitalEnrolling: 10321 location
RECRUITINGNCT06836011

A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence,...

The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral...

Sponsor: Medical University of ViennaEnrolling: 6008 locations

Frequently Asked Questions

There are currently 3 clinical trials for Mitral Regurgitation, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Mitral Regurgitation, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Mitral Regurgitation, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.